Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch

The U.S. stock market has recently experienced volatility, driven by trade policy uncertainties and fluctuating corporate results, with tariffs on Mexico being delayed as a temporary relief. Amidst this backdrop, penny stocks continue to attract attention for their potential to offer growth opportunities in smaller or emerging companies. While the term "penny stocks" may seem outdated, these investments can still provide value when backed by strong financial health and a clear growth trajectory.

Top 10 Penny Stocks In The United States

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Adlai Nortye (NasdaqGM:ANL)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Adlai Nortye Ltd. is a clinical-stage biotechnology company dedicated to discovering and developing cancer therapies in the United States and Mainland China, with a market cap of $78.23 million.

Operations: Adlai Nortye Ltd. has not reported any revenue segments.

Market Cap: $78.23M

Adlai Nortye Ltd., a clinical-stage biotech firm, is pre-revenue with no significant income streams and remains unprofitable. Despite this, the company has more cash than total debt and maintains a sufficient cash runway for over a year. Recent executive changes include the appointment of Dr. Alex Ye as interim CFO, bringing extensive biopharma experience to the role. The firm's short-term assets exceed its liabilities, but it faces challenges with high volatility in share price and an inexperienced management team. Shareholders have not experienced significant dilution recently, yet earnings have declined annually by 12.7% over five years.

• Click here to discover the nuances of Adlai Nortye with our detailed analytical financial health report.
• Examine Adlai Nortye's earnings growth report to understand how analysts expect it to perform.

InflaRx (NasdaqGS:IFRX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing C5a inhibitor technology in Germany and the United States, with a market cap of approximately $141.91 million.

Operations: The company's revenue is derived entirely from its Pharmaceuticals segment, amounting to €0.17 million.

Market Cap: $141.91M

InflaRx N.V., a clinical-stage biopharmaceutical company, is pre-revenue with earnings below US$1 million and remains unprofitable. The firm recently achieved a significant milestone with the European Commission granting marketing authorization for GOHIBIC® under exceptional circumstances, marking it as the first approved treatment in the EU for SARS-CoV-2-induced ARDS. Despite this progress, InflaRx faces challenges such as high share price volatility and limited cash runway of less than a year. The company's short-term assets exceed its liabilities, and it operates without debt, providing some financial stability amidst ongoing development efforts.

• Take a closer look at InflaRx's potential here in our financial health report.
• Understand InflaRx's earnings outlook by examining our growth report.

Inuvo (NYSEAM:INUV)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Inuvo, Inc. operates in the advertising technology and services sector primarily within the United States and has a market cap of $68.83 million.

Operations: The company generates revenue from its Software & Programming segment, totaling $78.45 million.

Market Cap: $68.83M

Inuvo, Inc. has made strides in the advertising technology sector with its recent enhancement of IntentKey, introducing zip code-level audience insights that offer privacy-compliant targeting solutions amid the decline of traditional cookies. Despite these advancements and a revenue forecast growth of 19.63% annually, Inuvo remains unprofitable with increasing losses over five years and a cash runway under one year unless free cash flow grows significantly. The company's short-term assets fall short of covering liabilities, yet it benefits from experienced management and no debt burden, positioning it as an intriguing but risky penny stock investment opportunity.

• Get an in-depth perspective on Inuvo's performance by reading our balance sheet health report here.
• Gain insights into Inuvo's outlook and expected performance with our report on the company's earnings estimates.

Turning Ideas Into Actions

• Take a closer look at our US Penny Stocks list of 709 companies by clicking here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com